CRI Lifetree Chief Medical Director Dr. Lynn Webster Named President of the American Academy of Pain Medicine (AAPM)

CRI Lifetree Chief Medical Director Dr. Lynn Webster Named President of the American Academy of Pain Medicine (AAPM)

SALT LAKE CITY--(BUSINESS WIRE)--Dr. Lynn Webster, chief medical director of CRI Lifetree and co-founder of Lifetree Clinical Research, has been elected president of the American Academy of Pain Medicine (AAPM), the medical specialty society representing physicians practicing in the field of pain medicine. As a medical specialty society, the organization is involved in education, training, advocacy, and research in the specialty of pain medicine.

"The American Academy of Pain Medicine alone is uniquely positioned to effectively make a difference in these areas"
"Pain affects more people than heart disease, cancer, and diabetes combined," Webster said. "That means there are vast needs — people needlessly suffering — and as leading experts in pain care, the academy can make a difference."

Webster said he hopes to use his term to lead the organization to make great strides during the coming year in several key areas:

Educating physicians and patients about safe prescribing and use of pain medications
Improving the health care delivery systems so that comprehensive treatment is available to patients with chronic pain
Investigating new treatments that are safer and more effective
"The American Academy of Pain Medicine alone is uniquely positioned to effectively make a difference in these areas," Webster said.

Webster is a long-standing member of the board of directors of the American Academy of Pain Medicine and was instrumental in launching the Utah chapter. He also led the development of the organization's Safe Opioid Prescribing Initiative.

As Chief Medical Director for CRI Lifetree, Webster's research focuses on developing safer and more effective therapies for chronic pain and addiction. He is also a leading sleep researcher with particular interest in analgesic-induced sleep-disordered breathing.

About CRI Lifetree

CRI Lifetree is a leader in specialized, multi-therapeutic early stage research providing innovative solutions, high quality and timely results to sponsors. The company has significant expertise in pain disorders, human abuse liability testing, psychiatry and neurology, cognition and pediatrics. CRI Lifetree offers a broad range of Phase I-IV services and rapid access to specific patient populations to meet the requirements of complex clinical research programs. With sites in Marlton, N.J., Philadelphia and Salt Lake City, the company conducts inpatient and outpatient clinical research in special populations and healthy volunteers. For additional information, visit www.CRILifetree.com.

Contacts

SCORR Marketing
Lea Studer, 308-237-5567
[email protected]

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.